Seeking Alpha

Benjamin Paluch

View as an RSS Feed
View Benjamin Paluch's Comments BY TICKER:
Latest comments  |  Highest rated
  • Seeing Is Believing, The Future Of ACTC [View instapost]
    "That made them suspect that something else may be causing the seeming improvement, such as the anti-rejection drugs she was taking or the placebo effect. But they have since become more confident her improvement is indeed being caused by the cells."

    http://n.pr/wvVsbh
    Feb 23 08:47 PM | 2 Likes Like |Link to Comment
  • 2 Are Better Than 1: Endocyte Uses Diagnostics To Complements Its Drugs [View article]
    Dear Nitin,

    Thank you for your questions.

    According to company notes, research and development expenses includes clinical trials. Considering the number of active clinical trials (http://bit.ly/1bs1N9F), it is reasonable to assume the increase in R&D spending is due to clinical trial expenses such as patient accrual, drug administration, and data collection.

    Regarding specific milestones, ECYT announced yesterday an updated analysis of its PRECEDENT trial (http://bit.ly/1bs1N9H). Briefly, platinum-resistant ovarian cancer patients (10-100% FR) treated with EC145 and PLD had 5.7 months PFS compared to only 1.7 months in patients who received PLD only.

    Kind regards,
    Ben
    Oct 2 07:12 PM | Likes Like |Link to Comment
  • Competing In The Sport Of Biotechs, Curis Takes Aim [View article]
    Dear Hope4Future,

    Evasion of apoptosis, or programmed cell death, is unfortunately only one hallmark of cancer (there are, at least, five more). Recent evidence suggests IAPs may play an important role in the initiation and progression of cancer. Therefore, there is growing interest in targeting IAPS with a number of drugs in development.

    Please see,
    Hanahan, D. and R.A. Weinberg, Hallmarks of cancer: the next generation. Cell, 2011. 144(5): p. 646-74.
    Gyrd-Hansen, M. and P. Meier, IAPs: from caspase inhibitors to modulators of NF-kappaB, inflammation and cancer. Nat Rev Cancer, 2010. 10(8): p. 561-74

    Kind regards,
    Ben
    Jun 16 05:12 PM | Likes Like |Link to Comment
  • Complete Genomics, A Complete Future? [View article]
    Clifford A. Reid, Ph.D., is our co-founder and has served as our President, Chief Executive Officer and Chairman since July 2005 and as a member of our board of directors since July 2005. From March 2003 to September 2005, Dr. Reid was Vice President of Collaborative Solutions at Open Text Corporation, a software company. In 1995, Dr. Reid co-founded Eloquent, Inc., a digital video communications company, and served as its Chief Executive Officer until 1999 and as its Chairman until 2003, when it was acquired by Open Text. In 1988, Dr. Reid co-founded Verity, Inc., an enterprise text search engine company, and served as its Vice President of Engineering from 1988 to 1992 and as its Executive Vice President from 1992 to 1993. Dr. Reid received a B.S. in Physics from the Massachusetts Institute of Technology, an M.B.A. from Harvard University and a Ph.D. in Management Science and Engineering from Stanford University.

    http://bit.ly/QyshMd
    Aug 2 06:33 PM | Likes Like |Link to Comment
  • Seeing Is Believing, The Future Of ACTC [View instapost]
    Right. According to their 1st Quarter Conference Call, they have $11 million in cash with an additional $11 million in an equity commitment yet to be drawn down. To raise additional capital, they can either complete an equity financing or initiate a partnership unfortunately at the expense of current shareholders.
    Jul 31 07:33 AM | Likes Like |Link to Comment
COMMENTS STATS
5 Comments
0 Likes